ReviewJournal of clinical medicine2026
The Role of Ethanol Ablation of the Vein of Marshall in the Era of Pulsed Field Ablation.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide and is associated with significant morbidity, mortality, and health care expenditure. Catheter ablation is the most effective treatment strategy to decrease AF burden, a measure strongly correlated with significant clinical outcomes. For the last two decades, pulmonary vein isolation (PVI) has remained the cornerstone of the ablation procedure, with single procedure success rates as high as 90% in patients with paroxysmal AF. These favorable outcomes have not translated to patients with persistent AF, who harbor more atrial remodeling and who may require ablation beyond PVI. While most PVI-adjunctive ablation strategies have not survived the rigor of randomized control trials, in 2020, VENUS showed that adjunctive ethanol instillation into the vein of Marshall (EIVOM) improved clinical outcomes in patients with persistent AF. Since VENUS, three other randomized trials have consistently shown a benefit of adjunctive EIVOM, though utilization of this technique remains low due to a multitude of factors. In parallel to the mounting evidence supporting EIVOM, pulsed-field ablation (PFA) has revolutionized the landscape and has called into question the ongoing role of EIVOM. This review examines the electrophysiologic significance of the VOM and summarizes the clinical evidence supporting adjunctive EIVOM in the era of PFA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.